ArticleDiscover oncology2026
Construction and validation of a model based on necroptosis-related genes for predicting glioma prognosis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGliomas are highly aggressive brain tumors that pose significant challenges in terms of prognosis and treatment. The precise expression patterns and prognostic significance of necroptosis-related genes (NRGs) in gliomas remain poorly understood, despite necroptosis demonstrating promise as a therapeutic target in cancer.
methodsWe downloaded and preprocessed glioma datasets from TCGA (training cohort) and GEO (GSE43378, serving as an independent external validation cohort). An additional independent validation was performed using the Chinese Glioma Genome Atlas (CGGA) cohort. The KEGG, MSigDB, and GeneCards databases were utilized to develop an extensive list of NRGs. The necroptosis score (N-Score) and immune infiltration were assessed using single-sample GSEA. To identify prognostic genes, we performed WGCNA to identify necroptosis-related modules, followed by univariate Cox regression and LASSO-penalized multivariate Cox regression for gene selection.
resultsGlioma cases were assigned to high- and low-risk groups using the N-Score, and a marked difference in survival was observed (p < 0.001). We identified 11 prognostic genes (CASP6, DDIT3, FASN, FERMT1, GLUD1, GNLY, MYD88, NINJ1, PLA2G4A, PPIA, and TNFRSF1A) that were crucial for constructing a robust risk model that accurately predicts survival at one, two, and three years. Important hub genes, such as TNFRSF1A, were identified by the protein-protein interaction and mRNA-miRNA regulatory networks. These hub genes also showed strong correlations with different types of immune cells, such as myeloid-derived suppressor cells and central memory CD4 + T cells, suggesting that necroptosis may affect the tumor immune microenvironment.
conclusionNRGs are crucial in glioma prognosis and immune modulation. The risk model and identified hub gene TNFRSF1A provide valuable insights for further research and potential therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.